Local drug and gene delivery through microbubbles

Evan C Unger, Evan M Hersh, Mani Vannan, Terry O Matsunaga, Thomas McCreery

Research output: Contribution to journalArticle

237 Citations (Scopus)

Abstract

Ultrasound contrast agents (microbubbles) lower the threshold for cavitation by ultrasound energy. Ultrasound microbubbles may be used as cavitation nuclei for drug and gene delivery. By tailoring the physical properties of microbubbles and coating materials, drugs and genetic drugs can be incorporated into ultrasound contrast agents. As the microbubbles enter the region of insonation, the microbubbles cavitate, locally releasing the therapeutic agents. Cavitation also causes a local shockwave that improves cellular uptake of the therapeutic agent. As a result of the human genome project and continuing advances in molecular biology, many therapeutic genes have been discovered. In the cardiovascular system, gene therapy has the potential to improve myocardial vascularization and ameliorate congestive heart failure. For successful development of clinical gene therapy, however, effective gene delivery vectors are needed. Ultrasound contrast agents can be used to develop new, more effective vectors for gene delivery. Transthoracic ultrasound can be focused on the heart so that an intravenous injection of gene-bearing microbubbles will deliver genes relatively selectively to the myocardium. Using this technique, we have produced high levels of transgene expression in the insonated region of the myocardium. This new technology, using microbubbles and ultrasound for drug and gene delivery, merits further study and development.

Original languageEnglish (US)
Pages (from-to)45-54
Number of pages10
JournalProgress in Cardiovascular Diseases
Volume44
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Microbubbles
Pharmaceutical Preparations
Genes
Contrast Media
Genetic Therapy
Myocardium
Human Genome Project
Cardiovascular System
Transgenes
Intravenous Injections
Molecular Biology
Therapeutics
Heart Failure
Technology

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Local drug and gene delivery through microbubbles. / Unger, Evan C; Hersh, Evan M; Vannan, Mani; Matsunaga, Terry O; McCreery, Thomas.

In: Progress in Cardiovascular Diseases, Vol. 44, No. 1, 2001, p. 45-54.

Research output: Contribution to journalArticle

@article{d7aca9bd540b464cb275aab51c25ac7b,
title = "Local drug and gene delivery through microbubbles",
abstract = "Ultrasound contrast agents (microbubbles) lower the threshold for cavitation by ultrasound energy. Ultrasound microbubbles may be used as cavitation nuclei for drug and gene delivery. By tailoring the physical properties of microbubbles and coating materials, drugs and genetic drugs can be incorporated into ultrasound contrast agents. As the microbubbles enter the region of insonation, the microbubbles cavitate, locally releasing the therapeutic agents. Cavitation also causes a local shockwave that improves cellular uptake of the therapeutic agent. As a result of the human genome project and continuing advances in molecular biology, many therapeutic genes have been discovered. In the cardiovascular system, gene therapy has the potential to improve myocardial vascularization and ameliorate congestive heart failure. For successful development of clinical gene therapy, however, effective gene delivery vectors are needed. Ultrasound contrast agents can be used to develop new, more effective vectors for gene delivery. Transthoracic ultrasound can be focused on the heart so that an intravenous injection of gene-bearing microbubbles will deliver genes relatively selectively to the myocardium. Using this technique, we have produced high levels of transgene expression in the insonated region of the myocardium. This new technology, using microbubbles and ultrasound for drug and gene delivery, merits further study and development.",
author = "Unger, {Evan C} and Hersh, {Evan M} and Mani Vannan and Matsunaga, {Terry O} and Thomas McCreery",
year = "2001",
doi = "10.1053/pcad.2001.26443",
language = "English (US)",
volume = "44",
pages = "45--54",
journal = "Progress in Cardiovascular Diseases",
issn = "0033-0620",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Local drug and gene delivery through microbubbles

AU - Unger, Evan C

AU - Hersh, Evan M

AU - Vannan, Mani

AU - Matsunaga, Terry O

AU - McCreery, Thomas

PY - 2001

Y1 - 2001

N2 - Ultrasound contrast agents (microbubbles) lower the threshold for cavitation by ultrasound energy. Ultrasound microbubbles may be used as cavitation nuclei for drug and gene delivery. By tailoring the physical properties of microbubbles and coating materials, drugs and genetic drugs can be incorporated into ultrasound contrast agents. As the microbubbles enter the region of insonation, the microbubbles cavitate, locally releasing the therapeutic agents. Cavitation also causes a local shockwave that improves cellular uptake of the therapeutic agent. As a result of the human genome project and continuing advances in molecular biology, many therapeutic genes have been discovered. In the cardiovascular system, gene therapy has the potential to improve myocardial vascularization and ameliorate congestive heart failure. For successful development of clinical gene therapy, however, effective gene delivery vectors are needed. Ultrasound contrast agents can be used to develop new, more effective vectors for gene delivery. Transthoracic ultrasound can be focused on the heart so that an intravenous injection of gene-bearing microbubbles will deliver genes relatively selectively to the myocardium. Using this technique, we have produced high levels of transgene expression in the insonated region of the myocardium. This new technology, using microbubbles and ultrasound for drug and gene delivery, merits further study and development.

AB - Ultrasound contrast agents (microbubbles) lower the threshold for cavitation by ultrasound energy. Ultrasound microbubbles may be used as cavitation nuclei for drug and gene delivery. By tailoring the physical properties of microbubbles and coating materials, drugs and genetic drugs can be incorporated into ultrasound contrast agents. As the microbubbles enter the region of insonation, the microbubbles cavitate, locally releasing the therapeutic agents. Cavitation also causes a local shockwave that improves cellular uptake of the therapeutic agent. As a result of the human genome project and continuing advances in molecular biology, many therapeutic genes have been discovered. In the cardiovascular system, gene therapy has the potential to improve myocardial vascularization and ameliorate congestive heart failure. For successful development of clinical gene therapy, however, effective gene delivery vectors are needed. Ultrasound contrast agents can be used to develop new, more effective vectors for gene delivery. Transthoracic ultrasound can be focused on the heart so that an intravenous injection of gene-bearing microbubbles will deliver genes relatively selectively to the myocardium. Using this technique, we have produced high levels of transgene expression in the insonated region of the myocardium. This new technology, using microbubbles and ultrasound for drug and gene delivery, merits further study and development.

UR - http://www.scopus.com/inward/record.url?scp=0034860986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034860986&partnerID=8YFLogxK

U2 - 10.1053/pcad.2001.26443

DO - 10.1053/pcad.2001.26443

M3 - Article

C2 - 11533926

AN - SCOPUS:0034860986

VL - 44

SP - 45

EP - 54

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

SN - 0033-0620

IS - 1

ER -